Therefore, BAFF-targeted therapies, such as belimumab, atacicept, and tabalumab, are being explored in clinical trials for conditions like chronic lymphocytic leukemia (CLL) and multiple myeloma. The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.